Lucile Dzen
Inventiva (France) · 12 works · 174 citations · h-index 4
Top works
- The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis
- Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
- Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment
- Biomarkers of Histological Response in Lanifibranor-treated Patients With Metabolic Dysfunction-associated Steatohepatitis
- 830-P: The Pan-PPAR Agonist Lanifibranor Improves Nonalcoholic Steatohepatitis (NASH) and Glycemic Control
- Correlation between severity of hepatic steatosis and markers of cardiometabolic health, and effect of lanifibranor therapy in patients with non-cirrhotic NASH
- The pan-PPAR agonist lanifibranor improves markers of cardiometabolic health in patients with NASH independent of weight change
- Lanifibranor therapy reduces the FibroScan-aspartate aminotransferase (FAST) score associated with histological ‘NASH resolution and improvement of fibrosis’ and biomarker response
- Early aminotransferase improvement in the phase 2b NATIVE study is predictive of response pattern of liver histology as well as hepatic and cardiometabolic health markers at the end of treatment in patients with non-cirrhotic NASH
- Identification of biomarkers of histological response in patients with non-cirrhotic NASH treated with Lanifibranor
- 844-P: Lanifibranor Improves Markers of Cardiometabolic Health in Patients with NASH and Type 2 Diabetes, Correlated with Responses in Adiponectin Levels
- SAT-206 Improvements in MACK-3, a diagnostic test for active metabolic dysfunction-associated steatohepatitis, parallel response to lanifibranor therapy